若生智能
Drug Database
DI

diphtheria+tetanus+pertussis combined vaccine

✓ Approved

China National Pharmaceutical · 细胞治疗 · 细胞治疗

什么是 diphtheria+tetanus+pertussis combined vaccine？

diphtheria+tetanus+pertussis combined vaccine 是一种细胞治疗，由China National Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司China National Pharmaceutical
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, China National Pharmaceutical

治疗适应症

diphtheria+tetanus+pertussis combined vaccine 针对 3 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedZhongguo shi yan xue ye xue za zhi2026-08-03

[Epidemiological Characteristics and Trends of HBV Among Blood Donors in Wuhan, 2016-2024].

Yu Qin Q, Xu Ting-Ting TT, Yang Hao H, Yu Xin X et al.

To analyze the seroepidemiological characteristics and trends of hepatitis B virus (HBV) infection among blood donors in Wuhan from 2016 to 2024, providing data support for monitoring blood safety and evaluating the effectiveness of blood screening. A total of 2 026 372 blood samples from Wuhan Blood Center from January 2016 to December 2024 were analyzed. The blood samples were tested using two enzyme-linked immunosorbent assay (ELISA) kits for hepatitis B surface antigen (HBsAg) and one nucleic acid testing (NAT) kit. Samples with reactive results in both HBsAg ELISA tests were defined as HBsAg-positive, while samples with non-reactive HBsAg but reactive HBV NAT results were defined as NAT-positive. HBV prevalence was calculated per 100 000 donations. Demographic characteristics such as age, sex, and marital status, as well as birth cohort and donation frequency were collected, and the characteristics and temporal trends of HBV infection among blood donors were analyzed. The χ2 test was used to assess differences in HBV prevalence across subgroups. Temporal trends in HBV prevalence were analyzed by linear regression. Risk factors associated with HBV infection were identified using logistic regression. From 2016 to 2024, there were 5 237 HBV-positive cases among blood donors in Wuhan, with an overall prevalence of 258.44 per 100 000 donations. This included 3 945 HBsAg-positive cases (prevalence: 194.68 per 100 000 donations) and 1 292 NAT-positive cases (prevalence: 63.76 per 100 000 donations). HBsAg prevalence initially declined (2016-2021), followed by a slight increase (2022-2024), with the rate of 2024 (224.50 per 100 000 donations) being 28.25% lower than that in 2016 (312.90 per 100 000 donations). Univariate analysis showed that male donors (OR=1.490, 95%CI: 1.400-1.586, P<0.001) and married donors (OR=4.060, 95%CI: 3.824-4.311, P<0.001) had a significantly higher risk of HBV infection. The risk of HBV infection increased with age, and the highest risk was observed in donors aged over 45 years (OR=8.138, 95%CI: 7.473-8.862, P<0.001). Donors born after 1992 (OR=0.336, 95%CI: 0.314-0.359, P<0.001), repeat donors (OR=0.094, 95%CI: 0.085-0.103, P<0.001), ethnic minority donors (OR=0.660, 95%CI: 0.565-0.772, P<0.001) and AB blood type donors (OR=0.850, 95%CI: 0.764-0.946, P=0.003) had a significantly lower risk of HBV infection. Age-stratified trend analysis showed a significant decline in HBsAg prevalence in the 18-25 years group (β=-0.930, P<0.001), 26-35 years group (β=-0.885, P=0.001), and 36-45 years group (β=-0.792, P=0.011), but no significant temporal trend was found in the group over 45 years old. The trends of HBV NAT prevalence in all age groups were not significant. HBsAg prevalence declined significantly in unmarried donors and those born after 1992 (β=-0.888, P=0.001； β=-0.896, P=0.001). Except for unmarried donors and male donors, HBV NAT prevalence showed a significant increasing trend across all other demographic subgroups. From 2016 to 2024, significant differences in HBV prevalence were observed across various demographic groups among blood donors in Wuhan, though the overall prevalence remained relatively low. This is attributed to the widespread administration of hepatitis B vaccination and the continuous strengthening of blood safety measures. Optimizing the recruitment strategy for blood donors will help further reduce the risk of HBV transmission through blood transfusion.

PMID 42544677
阅读全文 →
PubMedHuman vaccines & immunotherapeutics2026-08-03

Addressing HPV vaccine hesitancy and misinformation in India through public health communication strategies.

Jindal Robin R, R Ragendu R, Ghanghas Naman N, Gupta Raktima R et al.

India witnessed a significant step forward in cervical cancer prevention and human papillomavirus (HPV) vaccine coverage with the rollout of a nationwide free HPV vaccination drive aimed at vaccinating 14‑y‑old girls. However, the campaign's success rate can be significantly reduced if timely measures to tackle vaccine hesitancy and related misinformation are not taken into account. This commentary article discusses the effects of HPV vaccine misinformation, identifies global vaccine hesitancy factors, and highlights behavioral determinants affecting HPV vaccine hesitancy and its coverage in India. It identifies low awareness, misconceptions, sociocultural beliefs, stigma, safety concerns, weak injunctive norms, parental resistance, urban-rural disparities, and health system barriers as key challenges associated with vaccine hesitancy and low vaccine uptake among adolescents in India. Using an integrated Health Belief Model (HBM) and COM-B theoretical framework, it proposes a culturally sensitive, evidence-based multifactorial communication strategy focused on raising awareness, building trust, countering misinformation, capacity building of healthcare providers, and enhancing opportunities for the adoption of HPV preventive behavior. The commentary highlights the need to actively engage parents, adolescents, healthcare providers, educators, influencers, media, and community members to strengthen vaccine confidence, social norms, and support India's broader cervical cancer prevention goals in alignment with WHO's 90-70-90 targets by 2030.

PMID 42544634
阅读全文 →
PubMedJournal of pediatric endocrinology & metabolism : JPEM2026-08-03

Vaccine antibody responses in children with inborn errors of metabolism on protein-restricted diets: an overlooked silent risk?

Yılmazbaş Nimet Pınar NP, Çakar Nafiye Emel NE, Yıldız Sevil S, Karamanlı Gamze G et al.

Despite routine vaccination recommendations, concerns remain about vaccine-induced immune responses in some patients with inborn errors of metabolism (IEM). Therefore, antibody levels against vaccine antigens should be monitored to detect possible immune dysfunction. The aim of this study is to evaluate the vaccine antibody responses among children with IEM who have to follow protein restricted diet, and to compare with those in healthy children, and also to identify the factors affecting vaccine antibody responses in these patients. Anti-HBs and measles immunoglobulin G results of 25 patients diagnosed with amino acid metabolism disorder; phenylketonuria, organic acidemia, homocystinuria and urea cycle disorder, and 58 healthy children of the same age and gender were recorded. Seropositivity rates and titers were compared between two groups, and also with age, daily protein intake, diet duration, total protein, albumin and hemoglobin levels. Seropositivity against hepatitis B was 64 %, and against measles was 80 % in the patient group, and these seropositivity rates were lower than those in the control group. These results show that the trend of the findings was maintained even after adjustment for age. No significant differences in vaccine antibody responses was found among disease subgroups. As children receiving long-term protein-restricted diets may demonstrate reduced vaccine antibody responses, these findings warrant confirmation in larger prospective studies. We believe that vaccine antibody responses should also be reviewed during metabolic follow-up in these patients.

PMID 42544393
阅读全文 →
PubMedCellular and molecular biology (Noisy-le-Grand, France)2026-08-03

Pomegranate seed oil combined with low-frequency electromagnetic field enhances apoptosis in HT29 colon cancer cells via modulating caspase-3, caspase-9, Bax, and Bcl-2 expression.

Ghorbani Neda N, Baharara Javad J, Lotfi Maryam M

Colon cancer is one of the most prevalent cancers globally, characterized by the abnormal growth of cells in the intestines. Numerous studies have explored the effects of pomegranate-derived products, such as pomegranate seed oil (PSO), as anti-proliferative, anti-invasive, and pro-apoptotic agents against various cancer cell lines. Additionally, previous research has highlighted the anti-cancer properties of low-frequency electromagnetic fields (LF-EMF). In the present study, we investigated the combined effects of these two factors on the expression of the Caspase 3, Caspase 9, BAX, and Bcl2 genes. Human colon cancer cells of the HT29 line were sourced from the Pasteur Institute of Iran cell bank and maintained in a complete culture medium. The cells were categorized into four groups: control, PSO, EMF, and PSO+EMF. To assess cell viability and the type of cell death, MTT and Annexin V-FITC assays were employed. Changes in the expression levels of Caspase 3, Caspase 9, BAX, and Bcl2 were analyzed using Real-Time PCR. The results from the MTT and Annexin V-FITC assays indicated that both PSO and EMF reduced cell viability and promoted apoptosis in colon cancer cells. The Real-Time PCR results showed an upregulation of Caspase 3, Caspase 9, and BAX genes, along with a downregulation of Bcl2 expression in the treatment groups compared to the control group. This study demonstrated that the combination of PSO and EMF enhances apoptotic gene expression, thereby diminishing the proliferation and viability of cancer cells. Based on these findings, both PSO and LF-EMF exhibit cytotoxic effects on colon cancer cells, suggesting their potential as candidates for future research in the field of colon cancer.

PMID 42545143
阅读全文 →
PubMedPsychology & health2026-08-03

Predicting parents' COVID-19 vaccination intentions and behavior for their children: application of an integrated social cognition model.

Griffith Zoe M ZM, Royer Zoe Z, Gaffney Amber M AM, Hagger Martin S MS

Identifying modifiable determinants of parent-for-child vaccination may inform interventions for ongoing management of infectious diseases including COVID-19. We tested an integrated theoretical model in which social cognition constructs (coping appraisals, anticipated regret, moral norms) mediated effects of dispositional constructs (political orientation, conspiracy beliefs, vaccine hesitancy) on parent-for-child COVID-19 vaccination intention and behaviour. In a prospective correlational study, US parents (N = 497) with an unvaccinated child completed political orientation, conspiracy beliefs, vaccine hesitancy, and social cognition construct measures referring to COVID-19 vaccination for their child. Parents reported their vaccination behaviour for their child five weeks later. Consistent with predictions, we observed indirect effects of political orientation and vaccination hesitancy on intentions mediated by coping efficacy, anticipated regret, and moral norms, and sums of indirect effects of political orientation, conspiracy beliefs, and vaccine hesitancy on intention mediated by social cognition constructs. We also observed a sum of indirect effects of vaccine hesitancy on behaviour. Findings contribute to an evidence base for the effects of dispositional and social cognition constructs of parent-for-child COVID-19 vaccination intentions and behaviour and signal a candidate mechanism. Findings may provide formative evidence for developing interventions to manage childhood COVID-19 infection rates.

PMID 42543244
阅读全文 →
PubMedEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026-08-03

Facial nerve canal paragangliomas: a reconstruction-focused management approach and proposed decision-making framework.

Braude Rachel R, Manzie Timothy Gh TG, Shein Greg G, Charters Emma E et al.

To evaluate outcomes of early integration of facial nerve management for facial nerve canal paragangliomas (FNC PGLs), prioritising facial nerve rehabilitation alongside tumour control. A retrospective case series was conducted at the Sydney Head and Neck Cancer Institute and Sydney Facial Nerve Service, Chris O'Brien Lifehouse. Three patients with FNC PGLs underwent multidisciplinary assessment including imaging, biochemical evaluation, and SDHx genetic testing. Surgical planning integrated tumour treatment with facial nerve reconstruction. Dynamic procedures (cross-facial nerve grafts, masseteric and hypoglossal transfers, interpositional grafts) were combined with static techniques (tensor fascia lata slings, eyelid weights, brow lifts). Outcomes were assessed using House-Brackmann (HB) grading, Speech Handicap Index (SHI), Oral Competence Questionnaire (OCQ), speech intelligibility, and speech error analysis. All patients demonstrated improved facial nerve function, from preoperative HB grades IV-VI to HB III postoperatively, with a mean time to movement of 7 months (SD 4). Mean speech intelligibility improved from 78.3% to 86.7%, with corresponding improvements in SHI and OCQ scores. Static procedures restored resting symmetry, eye closure, and midface tone, while dynamic reanimation enabled spontaneous or volitional movement. No major treatment-related complications occurred. Tumour control was maintained in all patients at 60-68 months follow-up. Early integration of facial nerve management in FNC PGLs may attain durable tumour control while achieving meaningful improvement in facial nerve function. Early integration of facial nerve rehabilitation within a multidisciplinary framework improves oncologic and functional outcomes. Level 4.

PMID 42543428
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diphtheria+tetanus+pertussis combined vaccine